What’s new

• Zenith board approved amalgamation with Achyut Healthcare, net worth ₹35.06 cr vs Zenith's ₹7.42 cr.
• Share swap ratio: 119 Zenith shares for every 50 Achyut shares; post-merger share count jumps from 5.37 cr to 62.81 cr.
• Promoter holding to rise to 45.8% from 28.74%, strengthening control.

Why it matters

This is not a routine merger of near-peers. Zenith, with a market cap of ₹17 cr and trailing revenue declining 23.4%, is absorbing a company with ₹35 cr in net worth. Post-merger, the business may look fundamentally different, with access to Achyut's regulated export markets. But the massive dilution means current shareholders see their stake shrink proportionately. For a stock trading at 3477x P/E, this could spur a re-rating or confusion. The decisive factor will be Achyut's profitability and how the merged entity performs.

What we’re watching

• NCLT approval timeline — any delays could unsettle the stock.
• Revenue and earnings track record of Achyut; the filing gives net worth but not profit numbers.
• How the market absorbs the dilution re-rating: will the stock adjust before or after the scheme is effective?

The full read

Zenith Healthcare has approved a scheme to merge Achyut Healthcare into itself. The numbers are stark: Zenith's market cap is ₹17 cr, its net worth ₹7.42 cr. Achyut brings in ₹35.06 cr of net worth and ₹38.09 cr in assets. To accommodate Achyut's shareholders, Zenith will issue over 57 crore new shares, increasing total from 5.37 crore to 62.81 crore shares. The exchange ratio: 119 Zenith shares for every 50 Achyut shares. Post-merger, promoter holding climbs to 45.8% from 28.74%. For a company with declining revenue (-23.4% trailing) and negligible profitability (P/E 3477x), this is a bet that Achyut's manufacturing and export access will reset the narrative. The deal needs NCLT sanction. Until then, the stock is priced for a transformation that could either create value or complicate a struggling nano-cap further.

Primary source: BSE · NSE